About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Antiviral Therapy
›
Top Articles
Antiviral Therapy
Pharmacology
,
Biology
,
Microbiology
1.6
(top 10%)
Impact Factor
1.8
(top 10%)
extended IF
77
(top 5%)
H-Index
1.2K
authors
3.3K
papers
56.4K
citations
2.2K
citing journals
13.7K
citing authors
Most Cited Articles of Antiviral Therapy
Title
Year
Citations
Silver Nanoparticles Inhibit Hepatitis B virus Replication
2008
295
Silver nanoparticles inhibit hepatitis B virus replication
2008
268
Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience
2018
216
Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir
2005
183
Response-Guided Therapy: Optimizing Treatment now and in the Future
2008
179
Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease
2007
175
Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment
2008
169
Human coronaviruses: what do they cause?
2007
167
Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis
2004
161
The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan
2000
160
Human Coronaviruses: What Do They Cause?
2007
153
Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome
2016
147
Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D
2010
143
Management of Antiviral Resistance in Patients with Chronic Hepatitis B
2004
139
Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods
2012
136
In vitro
Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA
1999
136
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study
2010
134
A Sustained Virological Response to Interferon or Interferon/Ribavirin Reduces Hepatocellular Carcinoma and Improves Survival in Chronic Hepatitis C: A Nationwide, Multicentre Study in Taiwan
2006
133
Hepatitis B surface antigen seroclearance during chronic HBV infection
2010
128
Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial
2008
125
HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B
2011
122
Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds
2006
122
Molecular genetics of HBV infection
2010
120
The World Health Organization's global strategy for prevention and assessment of HIV drug resistance
2008
120
In Vitro
Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents
2007
119
previous
2009
2010
2011
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.